• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent Health Appoints Seth R. Frank as Vice President, Investor Relations

    12/1/21 8:00:00 AM ET
    $EVH
    $HNGR
    $MDRX
    Other Consumer Services
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $EVH alert in real time by email

    WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community.

    "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-term relationships with institutional investors, analysts and other stakeholders across the health care services sector, as well as health care information technology specifically. With his expertise in originating strategic IR programs, we anticipate Seth will accelerate the investment community's knowledge of Evolent's business as we continue to deliver on our strategy to create long-term value for shareholders." 

    Seth joins Evolent from Hanger, Inc. (NYSE:HNGR), a leading provider of orthotic and prosthetic services, where he served as Vice President of Treasury and Investor Relations for nearly four years. Previously, Seth was Vice President of Investor Relations at Allscripts (NASDAQ:MDRX), a health care information technology company, for nearly eight years; prior to that, Seth worked in several other investor relations and financial communications roles. Prior to beginning his corporate career in 2006, Seth was an equity analyst and capital markets professional at several firms including Morgan Stanley, SunTrust and A.G. Edwards where he covered the health care information technology, distribution and medical technology industries. Seth received his undergraduate degree from Emory University, an M.S. as a Physician Assistant from the University of Colorado School of Medicine, and also attended the Master of Public Health program at Yale University. He holds the Investor Relations Charter (IRC®) from the National Investor Relations Institute. 

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    About Evolent Health

    Evolent Health (NYSE:EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

    CONTACTS:

    Investors:

    Seth R. Frank

    Vice President, Investor Relations

    Evolent Health, Inc.

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-appoints-seth-r-frank-as-vice-president-investor-relations-301434968.html

    SOURCE Evolent Health

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVH
    $HNGR
    $MDRX

    CompanyDatePrice TargetRatingAnalyst
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Evolent Health Inc
    $EVH
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    Evolent Health Inc
    $EVH
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    Evolent Health Inc
    $EVH
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    Evolent Health Inc
    $EVH
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    Evolent Health Inc
    $EVH
    4/22/2024$40.00Buy
    Citigroup
    Veradigm Inc.
    $MDRX
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    Evolent Health Inc
    $EVH
    3/1/2024$45.00Outperform
    Oppenheimer
    More analyst ratings

    $EVH
    $HNGR
    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Guertin Shawn M was granted 21,979 shares (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:18:32 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • New insider Guertin Shawn M claimed no ownership of stock in the company (SEC Form 3)

      3 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:17:22 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M was granted 21,979 shares, increasing direct ownership by 152% to 36,437 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:14:47 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:20:54 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:18:12 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:16:20 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    $HNGR
    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

      Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thi

      6/20/25 6:30:00 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Veradigm to Release Business Update June 23rd and Host Investor Call June 24th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan

      6/18/25 5:27:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare

      Podcast supports company's mission to transform health insightfully, offering expert perspectives and proven strategies to help improve outcomes and reduce costs Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, a

      6/5/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology

    $EVH
    $HNGR
    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Evolent Health with a new price target

      Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

      1/10/25 7:49:47 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • BTIG Research reiterated coverage on Evolent Health with a new price target

      BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously

      12/3/24 7:52:53 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent Health downgraded by Stephens with a new price target

      Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously

      11/8/24 7:50:07 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary